Brief: Hillevax Reports Topline Data From NEST-IN1 Phase 2b Clinical Study Of HIL-214 In Infants
08/07/2024 13:31
July 8 (Reuters) - Hillevax Inc HLVX.O :
* HILLEVAX REPORTS TOPLINE DATA FROM NEST-IN1 PHASE 2B
CLINICAL
STUDY OF HIL-214 IN INFANTS
* HILLEVAX INC: EXPLORING POTENTIAL FOR CONTINUED
DEVELOPMENT OF
HIL-214 AND HIL-216 IN ADULTS
* HILLEVAX INC: NEST-IN1 CLINICAL STUDY DID NOT MEET ITS
PRIMARY
OR SECONDARY EFFICACY ENDPOINTS
* HILLEVAX INC: WILL DISCONTINUE FURTHER DEVELOPMENT OF
HIL-214 IN
INFANTS
Source text for Eikon: ID:nGNXy8N6L
Further company coverage: HLVX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HilleVax
See all newsBrief: XOMA Royalty Announces Closing Of Tender Offer For HilleVax
Brief: Hillevax Enters Into A Definitive Agreement To Be Acquired By Xoma Royalty For $1.95 In Cash Per Share Plus A Contingent Value Right
U.S. STOCKS ON THE MOVE-US energy sector, Oshkosh, Meta
U.S. STOCKS ON THE MOVE-Zumiez, BTC Digital, WesBanco
U.S. STOCKS ON THE MOVE-Petco Health, Smith & Wesson, Victoria's Secret